Ivana Pantelić, PhD

Dipl. farm. Milica Lukić

Position: Assistant Professor
Organizational unit: Depatment of Pharmaceutical Technology and Cosmetology
Room: B 309
Telefon: +381 113951 369
Fax: +381 11 3972 840
E-mail: ivana.pantelic@pharmacy.bg.ac.rs


Ivana Pantelić (maiden name Jakšić) graduated from Faculty of Pharmacy - University of Belgrade in 2007, where she also obtained her PhD in 2013 (module Pharmaceutical Technology) and specialist degree in Cosmetology (2018).

After graduation she worked as an intern in Pharmacy „Beograd”, and obtained her license in July 2008. From October 2007 she works at the Department of Pharmaceutical Technology and Cosmetology, Faculty of Pharmacy – University of Belgrade, first as a research assistant (2007-2009), then as a teaching assistant (2009-2016). In March 2016 she became Assistant Professor. At the Department of Pharmaceutical Technology and Cosmetology she is involved in integrated academic studies (courses: Pharmaceutical Technology 1, Cosmetology, Fundamentals of Pharmaceutical Biotechnology, Drug Dosage Forms for Paediatric Population), specialist academic studies in Cosmetology, and doctoral academic studies (modules Pharmaceutical Technology and Cosmetology).

During her PhD studies, in 2009 she obtained a scholarship of the German Academic Exchange Service (DAAD) for a research stay in Germany, within a special program entitled „Research experience in Germany for graduates and undergraduates from Serbia”. This collaboration with the Department of Pharmaceutical Technology of the Eberhard Karls University in Tübingen was continued through more research stays (2011, 2012, 2017).

Being active in writing project proposals, she was involved in 4 national (fundamental research, technological development, proof of concept) and 5 international projects (bilateral with Germany, COST action, JRC training and capacity building).

She is the editor of an international monograph and author/co-author of 36 peer reviewed scientific publications in high ranking international and national journals; 8 chapters in international scientific monographs/books; 8 technical solutions; many presentations at international and national scientific meetings.

Total citations: 354; h-index: 11 (source: SCOPUS, January 25th, 2021);

She is fluent in English (C2; Cambridge Certificate of Proficiency in English) and French (B2; Course de Langue et Civilisation Française de la Sorbonne).

  • Lemoine C, Thakur A, Krajišnik D, Guyon R, Longet S, Razim A, Gorska S, Pantelić I, Ilić T, Nikolić I, Lavelle E, Gamian A, Savić S, Milicic A. Technological approaches for improving vaccination compliance and coverage. Vaccines 2020;8(2):304. doi: 10.3390/vaccines8020304.
  • Pantelić I, Lukić M, Gojgić-Cvijović G, Jakovljević D, Nikolić I, Lunter DJ, Daniels R, Savić S. Bacillus licheniformis levan as a functional biomaterial in topical drug dosage forms: from basic colloidal considerations to actual pharmaceutical application. European Journal of Pharmaceutical Sciences 2020; 142: 105109; https://doi.org/10.1016/j.ejps.2019.105109

  • Schmidberger M, Nikolic I, Pantelic I, Lunter D. Optimization of Rheological Behaviour and Skin Penetration of Thermogelling Emulsions with Enhanced Substantivity for Potential Application in Treatment of Chronic Skin Diseases. Pharmaceutics 2019; 11 (8): pii: E361. doi: 10.3390/pharmaceutics11080361.

  • Ilić T, Pantelić I, Lunter D, Đorđević S, Marković B, Ranković D, Daniels R, Savić S. Critical quality attributes, in vitro release and correlated in vitro skin permeation - in vivo tape stripping collective data for demonstrating therapeutic (non)equivalence of topical semisolids: a case study of "ready-to-use" vehicles. International Journal of Pharmaceutics 2017; 528: 253-67; http://dx.doi.org/10.1016/j.ijpharm.2017.06.018

  • Jaksic I, Lukic M, Malenovic A, Reichl S, Hoffmann C, Müller-Goymann C, Daniels R, Savic S. Compounding of a topical drug with prospective natural surfactant-stabilized pharmaceutical bases: physicochemical and in vitro/in vivo characterization. A ketoprofen case study. European Journal of Pharmaceutics and Biopharmaceutics 2012; 80 (1): 164-175; doi:10.1016/j.ejpb.2011.09.001